ARS Pharmaceuticals, Inc. (SPRY) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

ARS Pharmaceuticals, Inc.

SPRY

NASDAQ

Unprofitable

Unprofitable

1B

Biotechnology

Next Earning date - 14 Nov 2024

1B

Biotechnology

Next Earning date - 14 Nov 2024

14.45USD

-0.01 ( -0.07%)

Relative Strenght

62

Volume Buzz

1%

Earning Acce

No

Dist 52w H.

12%

Quote Panel

Updated October 3, 2024

1W 0.91 % 1M 21.12 % 3M 58.79 % 1Y 261.25 %

Key Metrics

Market Cap
1.40B
Shares Outstanding
96.94M
Share in Float
48.66M
Dividende
0

Earning Date
14 Nov 2024
Price Target
14.45
Average Volume
1.11M
Beta
0.772438

Range
3.35-16.5
Industry
Biotechnology
Website
https://ars-pharma.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

2980.44x

P/S Ratio

6.50x

P/B Ratio

0.0

Debt/Equity

-9536.8%

Net Margin

$-0.5

EPS

How SPRY compares to sector?

P/E Ratio

Relative Strength

SPRY

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$58M

11581%

2025-Revenue

$0.85

-552%

2025-EPS

$24M

-54%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Cantor Fitzgerald

initialise

Previous: Not converted

2024-08-19

Now: Overweight

Raymond James

upgrade

Previous: Outperform

2024-08-12

Now: Strong Buy

Raymond James

initialise

Previous: Not converted

2024-07-25

Now: Outperform

Leerink Partners

upgrade

Previous: Not converted

2024-03-05

Now: Outperform

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.50
vs NA

Q4.22

N/A

-0.15
vs NA

Q1.23

N/A

-0.16
vs -0.70

Q2.23

N/A

-0.18
vs -0.55

Q3.23

N/A

-0.16
vs -0.50

Q4.23

N/A

-0.07
vs -0.15

Q1.24

N/A

-0.11
vs -0.16

Q2.24

N/A

-0.13
vs -0.18

Q3.24

N/A

-0.14
vs -0.16

Q4.24

N/A

-0.26
vs -0.07

Sales Growth

YoY

Current

Estimates

Q3.22

-64%

189K vs 528K

Q4.22

-275%

-1316000.00 vs 754K

Q1.23

-97%

20K vs 663K

Q2.23

-98%

10K vs 464K

Q3.23

-100%

NA vs 189K

Q4.23

+98%

-30000.00 vs -1316000

Q1.24

-100%

NA vs 20K

Q2.24

+4900%

500K vs 10K

Q3.24

NA

575K vs NA

Q4.24

+13626%

4.1M vs -30000

Return on Equity

QoQ

Q3.22

-25%

-0.25
vs 0.14

Q4.22

-5%

-0.05
vs -0.25

Q1.23

-4%

-0.04
vs -0.05

Q2.23

-7%

-0.07
vs -0.04

Q3.23

-6%

-0.06
vs -0.07

Q4.23

-3%

-0.03
vs -0.06

Q1.24

-5%

-0.05
vs -0.03

Q2.24

-6%

-0.06
vs -0.05

Institutionnal Ownership

Earnings Growth

Latest News

SPRY

accesswire.com

11 hours ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations

SPRY

accesswire.com

11 hours ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

SPRY

accesswire.com

11 hours ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations

SPRY

accesswire.com

11 hours ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Contact The Schall Law Firm

SPRY

accesswire.com

11 hours ago

The Schall Law Firm Urges Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

SPRY

accesswire.com

11 hours ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors Are Invited To Assist The Schall Law Firm

New Feature Coming Soon, Stay Tuned!

Shape

Shape